Stránka sa načítava...
Estrogen Receptor (SP1) Image Analysis Software User Manual, v. 5.1
Östrogenrezeptor (SP1) Handbuch zur Bildanalyse-Software-Anwendung, v. 5.1
Manuel d’utilisation de l’application logicielle d’analyse d’images du récepteur
d’œstrogènes (SP1), v. 5.1
Manual de usuario de la aplicación del software de análisis de imagen del receptor de
estrógeno (SP1), v. 5.1
Manuale dell’utente del software per l’analisi delle immagini
di Estrogen Receptor (SP1), v. 5.1
Uživatelská příručka softwarové aplikace pro analýzu obrazu estrogenového
receptoru (SP1), v. 5.1
Brugervejledning for Softwareapplikation til østrogenreceptor (SP1)-billedanalyse, v. 5.1
Εγχειρίδιο χρήσης της εφαρμογής του λογισμικού ανάλυσης εικόνας του οιστρογονικού
υποδοχέα (SP1), v. 5.1
Ösztrogén receptor (SP1) képelemző szoftveralkalmazás használati útmutató, v. 5.1
Gebruikershandleiding voor de oestrogeenreceptor (SP1)
beeldanalyse-softwareapplicatie, v. 5.1
Brukerhåndbok for bildeanalyseprogram for østrogenreseptor (SP1), v. 5.1
Podręcznik użytkownika oprogramowania użytkowego do analizy obrazu receptora
estrogenu (ER) (SP1), v. 5.1
Manual do utilizador para a aplicação do software para a análise de imagem do receptor de
estrogénio (SP1), v. 5.1
Priročnik za uporabo programske opreme za analizo slik estrogenskih
receptorjev (SP1), v. 5.1
Användarhandbok för programmet för bildanalys av östrogenreceptorn (SP1), v. 5.1
Not for distribution in the US
PS-001377/06449018001
Ventana Medical Systems, Inc. Part No.: 101407000 Rev. A
INTENTIONALLY BLANK
Companion Algorithm Estrogen Receptor (SP1)
Image Analysis Software User Manual, v. 5.1
Ventana Medical Systems, Inc. Part No.: 101407000 Rev. A
Companion Algorithm Estrogen Receptor (SP1) Image Analysis Software User Manual
Copyright
Copyright © 2014. Ventana Medical Systems, Inc. All rights reserved.
Trademarks
BENCHMARK, CONFIRM, COMPANION ALGORITHM, VENTANA ISCAN HT, ISCAN, VIRTUOSO,
VENTANA, and the VENTANA logo are trademarks of Roche. All other trademarks are the property of their respective
owners.
Companion Algorithm ER (SP1) image analysis software is licensed for use between Ventana Medical Systems, Inc. and
a licensee, and only users authorized there under are permitted to access and use the software. Unauthorized use and
distribution may result in civil and criminal penalties.
Open Source and Commercial Software
Refer to the Virtuoso Reference Guide for information on Open Source and Commercial Software programs.
Contact Information:
Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, AZ 85755
USA
+1 520 887 2155
www.ventana.com
Ventana Medical Systems, Inc.
203 Ravendale Drive
Mountain View, CA 94043
USA
Roche Diagnostics GmbH
Sandhofer Strasse 116
D-68305 Mannheim
Germany
+49 621 7590
Part No.: 101407000 Rev. A i
Table of Contents
About the Companion Algorithm ER (SP1) image analysis software . . . . . . . . . . . .1
Topics Covered in this Chapter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Who Should Read this Manual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Related Document . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Technical Support. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Connection Requirements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
Cyber Security . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
User Authorization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Securing Networks and Servers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Protecting Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
Chapter 1: Intended Use and Indications for Use . . . . . . . . . . . . . . . . . . . . . . . .5
Intended Use and Indications for Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Summary and Explanation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Test Principles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Warnings and Precautions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Pre-Analytical Variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Required Materials Not Provided. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Performance Characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Assay Cutoff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Chapter 2: ER Comparison and Reproducibility Studies . . . . . . . . . . . . . . . . . . . .9
ER Marker Studies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Staining Procedure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Study Devices and Samples for BenchMark XT Instrument and iScan Coreo Slide Scanner. . . 9
ER Concordance with BenchMark XT Instrument and iScan Coreo Slide Scanner . . . . . . . . . 9
Intra-System and Inter-System Studies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
ER Concordance with BenchMark ULTRA Instrument and iScan Coreo Slide Scanner . . . . . 12
Appendix A: Reagents (Antibody) Package Inserts. . . . . . . . . . . . . . . . . . . . . . .19
Reagents (Antibody) Package Inserts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21
ii Part No.: 101407000 Rev. A
Table of Contents ER (SP1) Image Analysis Software Users Manual
INTENTIONALLY BLANK
Part No.: 101407000 Rev. A 1
About the Companion Algorithm ER (SP1) image analysis
software
Welcome to the Companion Algorithm Estrogen Receptor (ER) (SP1) image analysis software User Manual.
Topics Covered in this Chapter
• Who Should Read this Manual (page 1)
• Introduction (page 1)
• Related Document (page 1)
• Technical Support (page 1)
• Connection Requirements (page 1)
• Cyber Security (page 2)
Who Should Read this Manual
System Administrators should read this user manual and use it for reference while operating the VENTANA Virtuoso software.
Introduction
The Companion Algorithm ER (SP1) image analysis software assists the pathologist in the semi-quantitative measurement of ER in
tissues stained with the Ventana Medical Systems, Inc. CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary
Antibody (CONFIRM anti-ER (SP1)). This application generates an ER score that can be reviewed and accepted by the pathologist,
or if necessary, overridden by the pathologist. The image analysis application is an assist to the pathologist in the scoring and
interpretation of ER staining on breast cancer tissues.
The Virtuoso Estrogen Receptor Digital Read Application allows the pathologist to view CONFIRM anti-ER (SP1) stained slides
as images on a computer monitor, similar to what can be viewed under a microscope. While reviewing the image, the pathologist
may change magnification and move freely about the image.
Related Document
For additional information on the Virtuoso software, see the following Ventana document:
• Virtuoso Reference Guide (PL-000123-EN)
Technical Support
Connection Requirements
Refer to the Virtuoso Reference Guide information on connection requirements.
Ventana Medical Systems, Inc.
1910 E. Innovation Park Drive
Tucson, AZ 85755
USA
Tel: +1 520 887 2155; for Technical Support, press 1
2 Part No.: 101407000 Rev. A
About the Companion Algorithm ER (SP1) image analysis software ER (SP1) Image Analysis Software User Manual
Cyber Security
Any device that is connected to a network (internally or externally) has the potential to be compromised by unauthorized access or
viruses. As with most devices, the software is designed to run on a computer utilizing Microsoft Windows and virus protection
software which requires the validation and implementation of the appropriate patches.
Some of the potential cyber security hazards are:
• Malicious software that alters the device software (such as viruses)
• Unauthorized access to the system that could compromise data safety
• Security of data transmitted over the Internet
Cyber security involves protecting data by preventing, detecting, and responding to malicious cyber attacks. Cyber attacks could
involve computer viruses which can completely erase data or hackers who alter files or even use the device as a host to attack other
devices. As serious as these hazards are, steps can be taken to maximize cyber security.
User Authorization
All software users must login with a valid user name and password. The user name and password are securely transmitted in
encrypted form over the Internet or Intranet. Once a user has logged in, the user remains active in the application until the user
explicitly logs out, closes the browser, or because the application closes after a period of inactivity.
Securing Networks and Servers
Network security consists of the provisions made in the computer network infrastructure, policies adopted by the network
administrator to protect the network, and the network resources that prevent unauthorized access.
The following are critical steps for securing a network server:
• Physical security (servers and network infrastructure behind locked doors)
• Use of robust passwords
• System and data backups (at regular intervals)
• Data protection
• Terminating unused services
• Restricting access to used services
The following are critical steps and methodologies used to secure network and servers:
• Data protection
• Data backups (at regular intervals)
• Refusal of automatic updates from off-the-shelf software
• Antivirus software for computers and servers
Protecting Data
Establishment of a network firewall and protection of the network against viruses using anti-virus software are effective methods to
protect data. Virus definitions should be kept up to date and regular scans of computers for spyware should be performed using a
legitimate anti-spyware application. If viruses or spyware are found, remove them immediately.
ER (SP1) Image Analysis Software User Manual About the Companion Algorithm ER (SP1) image analysis software
3
Evaluate Your Software Settings
The default settings of most software enable all available functionality. However, hackers may be able to take advantage of this
functionality to access devices. It is especially important to check the settings for software that connects to the Internet (browsers,
email clients, etc.). Apply the highest level of security available that still provides needed functionality.
Backup and Recovery
In order to develop a successful backup and recovery plan, comprehension of data accessibility needs and the potential impact of
data loss is essential. Automatic backup procedures need to be adopted using a data backup utility.
4 Part No.: 101407000 Rev. A
About the Companion Algorithm ER (SP1) image analysis software ER (SP1) Image Analysis Software User Manual
INTENTIONALLY BLANK
Part No.: 101407000 Rev. A 5
Chapter 1: Intended Use and Indications for Use
This chapter shows comparison and reproducibility studies for the ER marker.
Intended Use and Indications for Use
The Virtuoso system provides automated digital slide creation, management, analysis, and viewing. It is intended for in vitro
diagnostic use as an aid to the pathologist in the display, detection, counting, review and classification of tissues and cells of clinical
interest based on particular morphology, color, intensity, size, pattern and shape.
The IHC ER (SP1) Digital Read and Image Analysis applications are intended for use as an aid to the pathologist in the detection
and quantitative measurement of estrogen receptor (ER) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue.
ER results are indicated for use as an aid in the management, prognosis and prediction of therapy outcomes in breast cancer. When
used with Ventana Medical Systems, Inc. CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody, it
is indicated for use as an aid in the assessment of breast cancer patients for whom endocrine treatment is being considered (but is
not the sole basis for treatment).
Note: The IHC ER (SP1) Digital Read and Image Analysis applications are adjunctive computer-assisted methodologies for the
qualified pathologist in the acquisition and measurement of images from microscope glass slides of breast cancer specimens
stained for the presence of estrogen receptor protein. The pathologist should verify agreement with the Image Analysis
software application score. The accuracy of the test results depends on the quality of the immunohistochemical staining. It is
the responsibility of a qualified pathologist to employ appropriate morphological studies and controls as specified in the
instructions for the CONFIRM anti-Estrogen Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody assay used to assure the
validity of the iScan System for IHC ER Digital Read and Image Analysis scores. The actual correlation of CONFIRM anti-Estrogen
Receptor (ER) (SP1) Rabbit Monoclonal Primary Antibody to clinical outcome has not been established.
Summary and Explanation
The Virtuoso system for ER SP1 is an instrument and software system designed to assist the qualified pathologist in the consistent
quantitative assessment of protein expression in immunohistochemically (IHC) stained histologic sections from formalin-fixed,
paraffin-embedded (FFPE) normal and neoplastic tissues. The Virtuoso system can be used for review of digitized images of
histologic sections with image analysis algorithms (Companion Algorithm Virtuoso image analysis applications), or without
Companion Algorithm image analysis algorithms (Virtuoso Digital Read applications).
Digital Read applications present images on the computer screen in the same manner as one would see with a manual microscope,
inclusive of the pathologist's ability to select any areas of interest and the option of various magnification levels. For the Companion
Algorithm image analysis applications, the pathologist may use the system software to select and outline one or several field of views,
(FOVs), and each FOV may be viewed at various magnifications and then analyzed by the software (analysis at 20x magnification);
a count of the total number of target cells and the number interpreted by the algorithm as positive and negative is generated. The
pathologist can accept the score provided by the algorithm, or may override the score with a different score. The system requires
competent human intervention at all steps in the analysis process, and the software makes no independent interpretations of the data.
The Virtuoso system consists of a slide scanner, computer, monitor, keyboard, mouse, Companion Algorithm image analysis
algorithms, and software with a user interface. Virtuoso is an end-to-end digital pathology software solution that allows pathology
laboratories to acquire, manage, view, analyze, share, and report on digital images of pathology specimens. Using the Virtuoso
software, the pathologist can view digital images at various magnifications (as previously stated), add annotations, make tissue section
measurements, perform image analysis, and generate reports.
For in vitro diagnostic (IVD) use.
6 Part No.: 101407000 Rev. A
Chapter 1: Intended Use and Indications for Use ER (SP1) Image Analysis Software User Manual
Test Principles
The Companion Algorithm for ER (SP1) image analysis software employs image analysis techniques to obtain ER scoring.
Pre-defined parameters are used to obtain ER scores. The identification of the nucleus is carried out automatically by the image
analysis algorithms. The steps involved in the analysis algorithms are:
1. Enhancing the image. This process increases the contrast to make the image more suitable for analysis.
2. Identifying the epithelial area. The epithelial area is the region of the image where there is the possibility of epithelial cells
being present.
3. Identifying the nucleus.
4. Classifying the cells based on extent, intensity, and thickness of nuclear staining.
5. Computing the score.
Warnings and Precautions
It is important that glass slides with acceptable staining quality be used.
Pre-Analytical Variables
Tissue preparation and staining should follow the recommendations provided in the CONFIRM anti-ER (SP1) assay package insert.
For optimal image capture using the Virtuoso software, it is recommended that the tissue be free of folds and be placed on the slide
with a minimum of 2 mm boundary from the edge on all sides. The cover slip and slide label (if present) should not overhang the
edges of the slide. For further information on scanning, please refer to the appropriate iScan slide scanner reference guide.
Procedure
Refer to Virtuoso Reference Guide.
It is recommended that at least three fields of view be selected for analysis when using the Companion Algorithm ER (SP1) software.
Required Materials Not Provided
The Virtuoso system for ER SP1 requires use of CONFIRM anti-ER (SP1), and any additional material or supplies listed in the
package insert, to stain tissues prior to analysis.
The iScan Coreo slide scanner or the VENTANA iScan HT slide scanner is required for scanning of the slides.
Results
The Companion Algorithm ER SP1 image analysis software produces the overlay images and a staining score. The pathologist views
the overlay image and the instrument score, makes an assessment, and reports a score which may not be the same as the instrument
score. Refer to Virtuoso Reference Guide for an example of a report.
Limitations
The algorithms are designed to work for ER cell nuclei staining. The test results are only as good as the quality and accuracy of the
immunohistochemistry slide that is imaged, and the subsequent image that is analyzed. The pathologist must validate the CONFIRM
anti-ER (SP1) staining run by examination of the CONFIRM anti-ER (SP1) control images to verify that the expected results have
been obtained before images from patient slides are analyzed. The pathologist must follow the manufacturer's recommendations for
ER (SP1) Image Analysis Software User Manual Chapter 1: Intended Use and Indications for Use
Part No.: 101407000 Rev. A 7
CONFIRM anti-ER (SP1) including using all the positive and negative quality control materials for each staining run. If the control
slides are not acceptable, the patient tissues need to be re-stained with acceptable results. (See the CONFIRM anti-ER (SP1) package
insert for details about quality control recommendations.) The pathologist must follow the recommendations for surveying the
entire breast cancer specimen to assess any heterogeneity in the ER staining, the degree of background staining, cytoplasmic
staining, edge effect, etc. as recommended in the CONFIRM anti-ER (SP1) user's manual (available at www.ventana.com). If the
images captured have different staining (nuclear, cytoplasm, etc.), incorrect results will be generated. Incorrect results will also be
generated if the image quality cannot be analyzed. The software algorithms determine whether the quality of an image can be
analyzed, based on pre-defined parameters. Refer to the Virtuoso Reference Guide for more information.
The ER (SP1) image analysis algorithm will reject nuclei that are elongated regardless of the overall shape of the cell. For this reason,
tumors containing large numbers of cells with elongated nuclei may need to be evaluated manually. In addition, performance of the
Virtuoso system with the following types of breast cancers has not been evaluated: carcinoma in situ, carcinosarcoma, comedo
carcinoma, cystosarcoma phylloides, medullary carcinoma of the breast, mucinous variants of breast cancer, and spindle cell
carcinoma.
Performance Characteristics
Performance of the staining agent is described in the package insert for the CONFIRM anti-ER (SP1) staining process. See
Comparison and Reproducibility Studies in Chapter 2 for the description of the performance of the software.
Assay Cutoff
The performance of the Virtuoso system with ER SP1 was evaluated at the CAP/ASCO recommended clinical cutoffs: 0-0.99%
was considered a negative test result and 1-10% and >10% were considered positive test results.
8 Part No.: 101407000 Rev. A
Chapter 1: Intended Use and Indications for Use ER (SP1) Image Analysis Software User Manual
INTENTIONALLY BLANK
Part No.: 101407000 Rev. A 9
Chapter 2: ER Comparison and Reproducibility Studies
This chapter shows comparison and reproducibility studies for the ER marker.
ER Marker Studies
Staining Procedure
Refer to the CONFIRM anti-ER (SP1) package insert for the BenchMark XT, ULTRA and GX instruments, ultraView, and iView
detection kits.
Study Devices and Samples for BenchMark XT Instrument and iScan Coreo Slide Scanner
The ER comparison and reproducibility studies for the Virtuoso Digital Read and Companion Algorithm image analysis software
consisted of 120 de-identified archived breast carcinoma sections immunohistochemically stained with CONFIRM anti-ER (SP1).
Study test samples covered the ranges of 0-0.99%, 1-10% and >10%, and were interpreted at three different sites by three different
pathologists. All test slides were scanned at 20X magnification and all images were output in bif file format. For the image analysis
evaluation, a minimum of three fields of view were selected by each pathologist independently for each image.
ER Concordance with BenchMark XT Instrument and iScan Coreo Slide Scanner
The table below shows the concordance results for CONFIRM anti-ER (SP1) staining interpretation among three different sites:
1. Digital Read vs. Manual Method.
Table 2-1 Agreement - Digital Read vs. Manual (manual = true score).
Confusion Matrix
Digital
Site 1 Site 2 Site 3
(n = 114) (n = 116) (n = 114)
Neg Pos Neg Pos Neg Pos
Manual
Neg (0-0.99%) 52 7 49 5 45 11
Pos (1-10%, >10%) 0 55 2 60 2 56
% Agreement 94% 94% 89%
(95% CI) (88% - 97%) (88% - 97%) (81% - 93%)
10 Part No.: 101407000 Rev. A
Chapter 2: ER Comparison and Reproducibility Studies ER (SP1) Image Analysis Software User Manual
2. Image Analysis vs. Manual Method.
Intra-System and Inter-System Studies
The study was designed to demonstrate inter- and intra-Virtuoso system reproducibility for Virtuoso Digital Read and Companion
Algorithm image analysis applications. A designated subset of 40 cases that span the range of the ER scoring categories (0-0.99%,
negative, 1-10%, positive, and >10%, positive) were used.
1. Intra-pathologist/Inter-Day (pair-wise comparisons, Session1 vs. Session 2, Session1 vs. Session 3, Session 2 vs. Session 3).
Table 2-2 Agreement - Image Analysis vs. Manual (manual = true score).
Confusion Matrix
Image Analysis
Site 1 Site 2 Site 3
(n = 113) (n = 118) (n = 116)
Neg Pos Neg Pos Neg Pos
Manual
Neg. (0-0.99%) 56 2 56 0 52 3
Pos. (1-10%, >10%) 4 51 7 55 7 54
% Agreement 95% 94% 91%
(95% CI) (89% - 98%) (88% - 97%) (85% - 95%)
Table 2-3 Intra- Pathologist Digital Read.
Confusion Matrix
Intra-Pathologist Digital
Session 2 Session 3 Session 3
Neg Pos Neg Pos Neg Pos
18 20 17 22 17 22
Session 1
Neg 18 18 0 17 1
Pos 22 0 20 0 21
Session 2
Neg 18 17 1
Pos 20 020
% Agreement 100% 97% 97%
(95% CI) (91% - 100%) (87% - 100%) (87% - 100%)
ER (SP1) Image Analysis Software User Manual Chapter 2: ER Comparison and Reproducibility Studies
Part No.: 101407000 Rev. A 11
2. For Intra-Pathologist Image Analysis.
3. Inter-pathologist (pair-wise comparisons, Pathologist 1 vs. Pathologist 2, Pathologist 1 vs. Pathologist 3, Pathologist 2 vs.
Pathologist 3).
4. Inter-Pathologist Image Analysis.
Table 2-4 Intra-Pathologist Image Analysis.
Confusion Matrix
Intra-Pathologist Image Analysis
Session 2 Session 3 Session 3
Neg Pos Neg Pos Neg Pos
20 20 19 21 19 21
Session 1
Neg 20 19 1 19 1
Pos 20 1 19 0 20
Session 2
Neg 20 19 1
Pos 20 020
% Agreement 95% 98% 98%
(95% CI) (83% - 99%) (87% - 100%) (87% - 100%)
Table 2-5 Inter-Pathologist Digital Read.
Confusion Matrix
Inter-Pathologist Digital
Site 2 Site 3 Site 3
Neg Pos Neg Pos Neg Pos
51 65 47 67 47 67
Site 1
Neg 52 48 3 44 6
Pos 63 3 60 2 58
Site 2
Neg 51 41 8
Pos 65 558
% Agreement 95% 93% 88%
(95% CI) (89% - 98%) (86% - 96%) (81% - 93%)
Table 2-6 Inter-Pathologist Image Analysis.
Confusion Matrix
Inter-Pathologist Image Analysis
Site 2 Site 3 Site 3
Neg Pos Neg Pos Neg Pos
63 55 59 57 59 57
Site 1
Neg 60 59 1 55 4
Pos 54 2 52 3 51
Site 2
Neg 63 57 4
Pos 55 253
% Agreement 97% 94% 95%
(95% CI) (93% - 99%) (88% - 97%) (89% - 98%)
12 Part No.: 101407000 Rev. A
Chapter 2: ER Comparison and Reproducibility Studies ER (SP1) Image Analysis Software User Manual
ER Concordance with BenchMark ULTRA Instrument and iScan Coreo Slide Scanner
Study Devices and Samples for BenchMark ULTRA and iScan Coreo Slide Scanner
These ER (SP1) comparison studies for the Virtuoso Digital Read and Companion Algorithm image analysis software consisted of
120 de-identified archived breast carcinoma sections immunohistochemically stained with CONFIRM anti-ER (SP1) on the
BenchMark ULTRA instrument. Study test samples covered the ranges of 0-0.99%, 1-10% and >10%, and were interpreted by one
pathologist at one site. All test slides were scanned at 20X magnification and all images were output in bif file format. For the image
analysis evaluation, a minimum of three fields of view were selected by each pathologist independently for each image. 111 of 120
cases were able to be evaluated and were included in the analyses below.
The tables below shows the concordance results for CONFIRM anti-ER (SP1) assay stained on the BenchMark ULTRA instrument.
Digital Read vs. Manual
Image Analysis vs. Manual
Table 2-7 Agreement (ULTRA Instrument) - Digital Read vs. Manual
Manual Microscope Read
Digital Read
Positive Negative Total
Positive 69 1 70
Negative 1 40 41
Total 70 41 111
Positive Percent Agreement (PPA) n/N (%) (95% CI) 69/70 (98.6%) (92.3-99.7%)
Negative Percent Agreement (NPA) n/N (%) (95% CI) 40/41 (97.6%) (87.4-99.6%)
Overall Percent Agreement (OPA) n/N (%) (95% CI) 109/111 (98.2%) (93.7-99.5%)
Table 2-8 Agreement (ULTRA Instrument) - Digital Read vs. Manual
Manual Microscope Read
Digital Read
Positive Negative Total
Positive 64 4 68
Negative 6 37 43
Total 70 41 111
Positive Percent Agreement (PPA) n/N (%) (95% CI) 64/70 (91.4%) (82.5-96.0%)
Negative Percent Agreement (NPA) n/N (%) (95% CI) 37/41 (90.2%) (77.5-96.1%)
Overall Percent Agreement (OPA) n/N (%) (95% CI) 101/111 (91.0%) (84.2-95.0%)
ER (SP1) Image Analysis Software User Manual Chapter 2: ER Comparison and Reproducibility Studies
Part No.: 101407000 Rev. A 13
ER Concordance with BenchMark XT/ULTRA Instruments and VENTANA iScan HT Slide Scanner
Study Devices and Samples for BenchMark XT/ULTRA Instrument and iScan HT Slide Scanner
The ER comparison and reproducibility studies for the Virtuoso Digital Read and Companion Algorithm image analysis software
consisted of 30 de-identified archived breast carcinoma sections immunohistochemically stained with CONFIRM anti-ER (SP1).
Study test samples covered the ranges of 0-0.99% (negative), 1-10% (positive) and >10% (positive), and were interpreted at by one
pathologist. All test slides were scanned at 20X magnification and all images were output in bif file format. For the image analysis
evaluation, a minimum of three fields of view were selected by each pathologist independently for each image.
Digital Read vs. Manual
Image Analysis vs. Manual
Table 2-9 Agreement - Digital Read vs. Manual Microscopic Read
Manual Microscope Read
Digital Read
Negative Positive Total
Negative 13 1 14
Positive 1 14 15
Total 14 15 29
Positive Percent Agreement (PPA) n/N (%) (95% CI) 14/15 (93%) (70-99%)
Negative Percent Agreement (NPA) n/N (%) (95% CI) 13/14 (93%) (69-99%)
Overall Percent Agreement (OPA) n/N (%) (95% CI) 27/29 (93%) (78-98%)
Table 2-10 Agreement - Image Analysis vs. Manual Microscopic Read
Manual Microscope Read
Digital Read
Negative Positive Total
Negative 13 1 14
Positive 1 13 14
Total 14 14 28
Positive Percent Agreement (PPA) n/N (%) (95% CI) 13/14 (93%) (69-99%)
Negative Percent Agreement (NPA) n/N (%) (95% CI) 13/14 (93%) (69-99%)
Overall Percent Agreement (OPA) n/N (%) (95% CI) 26/28 (93%) (77-98%)
14 Part No.: 101407000 Rev. A
Chapter 2: ER Comparison and Reproducibility Studies ER (SP1) Image Analysis Software User Manual
ER Concordance with BenchMark GX Instrument, iScan Coreo, and iScan HT Slide Scanners
Study Devices and Samples for BenchMark GX Instrument, iScan Coreo, and iScan HT Slide Scanners
The ER comparison and reproducibility studies for the Virtuoso Digital Read and Companion Algorithm image analysis software
consisted of 30 de-identified archived breast carcinoma sections immunohistochemically stained with CONFIRM anti-ER (SP1)
Rabbit Monoclonal Primary Antibody. Study test samples covered the ranges of 0-0.99% (negative), 1-10% (positive) and >10%
(positive), and were interpreted by two pathologists. All test slides were scanned at 20X magnification and all images were output in
bif file format. For the image analysis evaluation, a minimum of three fields of view were selected by each pathologist independently
for each image.
The results were analyzed for each pathologist individually and also averaged across the two pathologists. The average overall percent
agreement (OPA) was determined as the weighted average for the two pathologists who independently scored the same cases, where
the weight of a pathologist's individual OPA rate was determined by the number of cases considered evaluable by that pathologist.
Digital Read vs. Manual Microscopic Read, iScan Coreo Slide Scanner
The average OPA for Digital Read vs. Manual Microscopic Read for iScan Coreo slide scanner was 96.5%.
Table 2-11 Pathologist #1 Agreement - Digital Read vs. Manual, iScan Coreo Slide Scanner
Digital Read
Manual Microscope Read
Negative Positive Total
Negative 16 1 17
Positive 0 10 10
Total 16 11 27
Overall Percent Agreement (OPA) n/N (%) (95% CI) 96.3%
Table 2-12 Pathologist #2 Agreement - Digital Read vs. Manual Microscopic Read,
iScan Coreo Slide Scanner
Digital Read
Manual Microscope Read
Negative Positive Total
Negative 18 0 18
Positive 1 11 12
Total 19 11 30
Overall Percent Agreement (OPA) n/N (%) (95% CI) 96.7%
/
